Avastin 100 mg Injection (Bevacizumab) — Targeted VEGF Inhibitor for Advanced Cancer Avastin 100 mg Injection contains bevacizumab, a targeted monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to reduce the blood supply to tumors, slowing tumor growth and improving response to treatment when combined with chemotherapy. It is indicated for use in adult patients with various advanced cancers, including metastatic colorectal cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, glioblastoma, and cervical cancer, among others. Administered as an intravenous infusion by trained oncology specialists, Avastin requires careful blood pressure monitoring, proteinuria testing, and clinical supervision to manage potential side effects such as hypertension, bleeding risk, and gastrointestinal discomfort.